AI-Driven EKG Screening for Dilated Cardiomyopathy
(DCM-DETECT Trial)
Trial Summary
What is the purpose of this trial?
This is a prospective, single-arm clinical trial in which participants with dilated cardiomyopathy will invite their first degree relatives to undergo mobile cardiac, electrocardiogram screening.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Mobile 6L AI-EKG Screening for detecting dilated cardiomyopathy?
Research shows that AI-enhanced electrocardiograms (ECGs) can effectively detect dilated cardiomyopathy (DC) with high sensitivity, meaning it can accurately identify those with the condition. This AI-ECG method is a simple and cost-effective screening tool, especially useful for identifying DC in patients and their close relatives.12345
Is AI-Driven EKG Screening for Dilated Cardiomyopathy safe for humans?
The research articles discuss various methods for assessing cardiac safety, focusing on potential heart-related risks of new drugs. These studies highlight the importance of early screening for heart risks, such as changes in heart rhythm or contractility, using advanced technologies. However, they do not provide specific safety data for AI-Driven EKG Screening for Dilated Cardiomyopathy or similar technologies.678910
How does the Mobile 6L AI-EKG Screening treatment differ from other treatments for dilated cardiomyopathy?
The Mobile 6L AI-EKG Screening treatment is unique because it uses artificial intelligence to analyze electrocardiograms (ECGs) for early detection of dilated cardiomyopathy, offering a simple and cost-effective alternative to traditional methods like echocardiography, which are more expensive and labor-intensive.12111213
Research Team
Roy Small, MD
Principal Investigator
Penn Medicine / Lancaster General Hospital
Eligibility Criteria
This trial is for people with dilated cardiomyopathy who will invite their close family members to participate in mobile heart screening using an AI-enhanced electrocardiogram (EKG).Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
DCM Screening
Participants undergo AI-enhanced 6Lead mobile electrocardiogram (EKG) screening to detect impaired left ventricular function
Follow-up
Participants are monitored for safety and effectiveness after screening, with a focus on cardiac follow-up
Treatment Details
Interventions
- Mobile 6L AI-EKG Screening (AI Screening)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Lancaster General Hospital
Lead Sponsor
Mayo Clinic
Collaborator